IBDEI0H2 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7627,1,3,0)
 ;;=3^Kidney Transplant Infection
 ;;^UTILITY(U,$J,358.3,7627,1,4,0)
 ;;=4^T86.13
 ;;^UTILITY(U,$J,358.3,7627,2)
 ;;=^5055711
 ;;^UTILITY(U,$J,358.3,7628,0)
 ;;=Z94.0^^52^514^8
 ;;^UTILITY(U,$J,358.3,7628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7628,1,3,0)
 ;;=3^Kidney Transplant Status
 ;;^UTILITY(U,$J,358.3,7628,1,4,0)
 ;;=4^Z94.0
 ;;^UTILITY(U,$J,358.3,7628,2)
 ;;=^5063654
 ;;^UTILITY(U,$J,358.3,7629,0)
 ;;=Z48.22^^52^514^1
 ;;^UTILITY(U,$J,358.3,7629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7629,1,3,0)
 ;;=3^Aftercare Following Kidney Transplant
 ;;^UTILITY(U,$J,358.3,7629,1,4,0)
 ;;=4^Z48.22
 ;;^UTILITY(U,$J,358.3,7629,2)
 ;;=^5063039
 ;;^UTILITY(U,$J,358.3,7630,0)
 ;;=Z52.4^^52^514^2
 ;;^UTILITY(U,$J,358.3,7630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7630,1,3,0)
 ;;=3^Kidney Donor
 ;;^UTILITY(U,$J,358.3,7630,1,4,0)
 ;;=4^Z52.4
 ;;^UTILITY(U,$J,358.3,7630,2)
 ;;=^5063082
 ;;^UTILITY(U,$J,358.3,7631,0)
 ;;=D47.Z1^^52^514^9
 ;;^UTILITY(U,$J,358.3,7631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7631,1,3,0)
 ;;=3^Post-Transplant Lymphoproliferative Disorder (PTLD)
 ;;^UTILITY(U,$J,358.3,7631,1,4,0)
 ;;=4^D47.Z1
 ;;^UTILITY(U,$J,358.3,7631,2)
 ;;=^5002261
 ;;^UTILITY(U,$J,358.3,7632,0)
 ;;=T86.10^^52^514^4
 ;;^UTILITY(U,$J,358.3,7632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7632,1,3,0)
 ;;=3^Kidney Transplant Complication,Unspec
 ;;^UTILITY(U,$J,358.3,7632,1,4,0)
 ;;=4^T86.10
 ;;^UTILITY(U,$J,358.3,7632,2)
 ;;=^5055708
 ;;^UTILITY(U,$J,358.3,7633,0)
 ;;=N18.1^^52^515^1
 ;;^UTILITY(U,$J,358.3,7633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7633,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 1
 ;;^UTILITY(U,$J,358.3,7633,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,7633,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,7634,0)
 ;;=N18.2^^52^515^2
 ;;^UTILITY(U,$J,358.3,7634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7634,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 2
 ;;^UTILITY(U,$J,358.3,7634,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,7634,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,7635,0)
 ;;=N18.3^^52^515^3
 ;;^UTILITY(U,$J,358.3,7635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7635,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3
 ;;^UTILITY(U,$J,358.3,7635,1,4,0)
 ;;=4^N18.3
 ;;^UTILITY(U,$J,358.3,7635,2)
 ;;=^5015604
 ;;^UTILITY(U,$J,358.3,7636,0)
 ;;=N18.4^^52^515^4
 ;;^UTILITY(U,$J,358.3,7636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7636,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 4
 ;;^UTILITY(U,$J,358.3,7636,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,7636,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,7637,0)
 ;;=N18.5^^52^515^5
 ;;^UTILITY(U,$J,358.3,7637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7637,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,7637,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,7637,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,7638,0)
 ;;=N18.9^^52^515^6
 ;;^UTILITY(U,$J,358.3,7638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7638,1,3,0)
 ;;=3^Chr Kidney Disease,Unspec
 ;;^UTILITY(U,$J,358.3,7638,1,4,0)
 ;;=4^N18.9
 ;;^UTILITY(U,$J,358.3,7638,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,7639,0)
 ;;=N18.6^^52^515^7
 ;;^UTILITY(U,$J,358.3,7639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7639,1,3,0)
 ;;=3^ESRD
 ;;^UTILITY(U,$J,358.3,7639,1,4,0)
 ;;=4^N18.6
 ;;^UTILITY(U,$J,358.3,7639,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,7640,0)
 ;;=N10.^^52^516^5
 ;;^UTILITY(U,$J,358.3,7640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7640,1,3,0)
 ;;=3^Acute Tubulo-Interstitial Nephritis
 ;;^UTILITY(U,$J,358.3,7640,1,4,0)
 ;;=4^N10.
